Subject Index

Acidosis
  cerebral ischemia and, 301
  metallothionen and, 403
Actinomycin D, neuronal viability and, 214
Adenosine
  endogenous, 24
  neuroprotection and, 41
  protection and, 1
Adenosine A_1 receptor agonists, ischemic brain disorders and, 23
Adenosine A_{2A} antagonists, therapy and, 43
Adenosine A_{2A} receptors, distribution and function of, 30
Adenosine A_3 agonist, nM concentrations and toxic effect of, 68
Adenosine A_3 receptor
  apoptosis and, 11
  brain and, 49
Adenosine amine congener (ADAC)
  ischemic brain damage and, 26
  optimum dose of, 69
Adenosine analogues, chemical structures of, 32
Adenosine receptor antagonists, chemical structures of, 33
Adenosine receptor subtypes, adenosine modulation of neurotransmission and, 12
Adenosine release, MCAO in cats and, 40
Adhesion molecules, gene expression induced by ischemia and, 185
Aging, neurological, melatonin and, 70
Aluminum fluoride (AlF_3), Alzheimer's dementia and, 152
Alzheimer's dementia, AlF_3 and NaF and, 152
Alzheimer's disease, melatonin and, 74
Amino acids, aromatic, melatonin and, 90
α-Amino-3-hydroxy-5-methylisoxasole-4-propionic acid (AMPA), TSEs and, 194
α-Amino-3-hydroxy-5-methylisoxasole-4-propionic acid (AMPA) antagonist, 394
α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid/kainic acid (AMPA/KA), 421
Animal models, 428
Anti-brain-derived neurotropic factor (anti-BDNF) antibodies, 239
Anticonvulsant, NBQX and, 398
Anti-tumor necrosis factor-α (TNFα), cerebral ischemia and, 207
Anxiety, NBQX and, 398
Anxiolytic activity, NBQX and, 396
Apoptosis
  adenosine A_3 receptor and, 11
  necrosis vs, 68
  neuregulins and, 358
  NMDA-induced neuronal cell death occurring via, 210
  penumbra and, 276
  TSE in cerebellum and, 199
Aptiganel, midazolam and, 420
ARL 15896AR, neuroprotective potential of, 220
Astrocyte functions, physiologically required, 6
Astrocytes, microglial cells and, 5
Astrocytic swelling, mechanisms and consequences of, 335
Astroglial cell death, adenosine A_3 receptor and, 14

Balanced entry characteristics, continuous assessment of, 316
Basic fibroblast growth factor (bFGF), neuroprotective properties of, 214
Basic fibroblast growth factor mRNA (bFGF mRNA), NMDA and, 217
Benzamide, PARP and, 373
Benzodiazepines
  neuroprotective properties of, 420
  toxicity of, 422
Bicuculline, hypoxia-ischemia and, 146
Biologically based model, 417
Bismuth, astrocytes and, 338
Blood flow
  cocaine dependence and, 323, 328
  reperfusion and, 424
Blood pressure, clomethiazole and, 420
Blood vessel inclusions, toxin-induced, 152
Brain, adenosine A_3 receptor and, 49
Brain damage, biochemical mediators of, 311
Brain edema, increased BBB permeability and, 258
Brain oxygen tension, RSR-13 and, 250
Brain penetration, 313
Brain pH, glutamate increase and, 280
Brain retraction, pharmacological therapy and, 290
Brain-derived neurotropic factor (BDNF) mRNA, subtoxic concentrations of NMDA and, 239

C57B1/6N mice, PARP and, 371
CA2 and CA1 hippocampal neurons, apparent differences in ischemic-induced damage of, 206
Cadmium, astrocytes and, 338

Calcium channel antagonists, calpain and, 132
Calcium channels, riluzole and, 382
Calcium homeostasis, neuronal physiology and dysfunction and, 136
Calcium influx, NMDA receptor-operated channel and, 2
Calcium overload, adenosine and, 2
Calcium-activated proteolysis, cerebrovascular disease and, 95
Calcium-mediated changes, MAP-2 and, 135
Calpain
  myelin breakdown and, 128
  tissue breakdown and, 121
Calpain substrates
  cerebral ischemia and, 95
  neuronal cell death and, 131
Calpain translocation, 132
Calpain-activated proteolysis, neonatal hypoxic-ischemia and, 104
Calpastatin, activity of calpains and, 104
Cell death
  delayed, dendritic dysfunction and, 138
  dorsal root ganglion and, 268
Cell death *in vivo*, PARP and, 404
Cellular localization, metallothioneins and, 338
Cerebellar granule cells, PARP and, 368
Cerebellum, ibogaine in, 197
Cerebral ischemia
  adenosine A_{2A} receptors and, 39
  single agents and, 290
Cerebral saline perfusion, brain edema formation and, 265
Cerebroplegia, cold, brain edema and, 264
Chemokine, stroke and, 186
Chinese hamster ovary (CHO) cells, HSP 70 and, 169
2-Chloroadenosine (2-CA), rat brain primary astrocytes and, 14
2-Chloro-2′-deoxyadenosine (2-CdA), apoptotic effect of, 17
Circumventricular organ (CVO), GLU and, 195
Cl-N^6-(3-iodobenzyl)-5′-(*N*-methylcarbamoyl-adenosine (Cl-IB-MECA), adenosine A_3 receptor and, 54
Cladribine-5′-triphosphate (2-CdATP), adenosine-induced apoptosis and, 17
Clinical trial, 429
Clinical trials, choosing compounds for, 314
Clomethiazole, stroke severity and, 419
Clozapine, NMDA receptor antagonists and, 425
Cocaine dependence
  neuroprotection and, 323
  subclinical neurological and neurovascular deficits in, 328
Cocktail, neuroprotective therapy and, 429
Comatose patients, melatonin and, 93
Combination therapy
  calpain inhibitors in SCI and, 125
  pharmacologic treatment of ischemia and, 301
Constant illumination, melatonin and, 92
Continuous data, 413
Contralateral hemisphere, unilateral ischemia and, 132
Contusion, intracranial, 309
Cortex damage, NBQX and, 400
Cortical noradrenaline, PARP and, 372
Cyclic adenosine monophosphate (cAMP), TNFα formation and, 208
Cyclic adenosine monophosphate (cAMP) signaling, t-ACPD and, 6
N^6-Cyclohexyladenosine (CHA), efficacious dose of, 69
N^6-Cyclopentyladenosine (CPA), efficacious dose of, 69
L-Cystiene, melatonin and, 73, 90
Cytokine, stroke and, 186
Cytotoxic properties, microglial cells and, 4

Darkness, melatonin protection of brain and, 91
'Delta Score,' 316
Demyelinating diseases, calpain and, 129
Dendritic dysfunction, neurodegeneration and, 134
Diaspirin cross-linked hemoglobin (DCLHb), lubeluzole and, 424
Diazepam, melatonin and, 91
Diffuse axonal injury, 305
2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo-(*F*)-quinoxaline (NBQX), 394
1,3-Dipropyl-8-cyclopentylxanthine (CPX), chronic treatment with, 25
DNA fragmentation, Cl-adenosine and, 5
Domoic acid, astrocytes injected with, 196
Dopamine D_1 and D_2 receptors, adenosine A_{2A} receptors and, 37
Dorsal root ganglion, visualizing dead cells inside, 268
Dose-response model, 415

Electroconvulsive therapy (ECT), melatonin and, 90
Eliprodil, neuroprotective effects of, 232
Energy deprivation, PARP and, 367
Enoxaparin, 391
Excitatory postsynaptic potentials (EPSP), eliprodil and, 233

Excitotoxicity
glutamate, 210
melatonin and, 85
Experimental allergic encephalomyelitis (EAE), neuregulin and, 403
Exploratory activity, NBQX and, 395

FDA guidelines, 406
Feline model, ischemic brain in, 241
Fluid-percussion model of brain injury, 332
Fluorine, protection against toxins and, 152
Focal brain ischemia, MK-801 and CGS 15943 and, 42
Focal ischemia/neuro-injury, ARL 15896AR and, 225
Fodrin, calpain-mediated proteolysis of, 105
Forebrain ischemia, ARL 15896AR and, 224
Free radicals, melatonin and, 70
Futility analysis, 317

G proteins, riluzole and, 385
Ganglioside GM_1, stroke and, 284
Gender, cocaine dependence and, 328
Gene expression
dendritic dysfunction and, 138
new, following focal stroke, 184
Glascow Outcome Score, efficacy end points and, 315
Glial cells, neuregulins and, 351
Global ischemia, ARL 15896AR and, 223
Glucocorticoid, stroke and, 284
Glutamate oxidative stress, melatonin and, 79, 93
Glutamate release, MCAO in cats and, 40
Glutamate-induced Ca^{2+} influx, PARP and, 370
Glutamate-induced neurotoxicity, PARP and, 367
Glutamine synthase (GS) recovery, 419
Growth factors, gene expression induced by ischemia and, 185
GV150526A, renal function and, 423

Heat shock proteins (HSP)
functional role of, 207
gene expression induced by ischemia and, 185
MPTP-induced neurotoxicity and, 167
Heavy metal cytotoxicity, metallothioneins and, 338
Hematoma
intracranial, 309
spontaneous intracerebral, 244
traumatic epidural and subdural, 244
Hemodilution, ischemic stroke and, 284
Heparin
head trauma and, 279
intracellular Ca^{2+} mobilization and, 279
low molecular weight, 389
High frequency stimulation (HFS), eliprodil and, 233
High-voltage-activated (HVA) Ca^{2+} channel currents, 405
Hippocampal damage, NBQX and, 401
Hippocampal slices, eliprodil and, 232
4-Hydroxyalkenals (4-HDA), melatonin and, 71
6-Hydroxydopamine lesion, SCH 58261 and, 38
Hypertension, nimodipine and, 420
Hyperthermia, brain edema formation and, 259
Hyperventilation, intraoperative neuroprotection and, 292
Hypothermia
methamphetamine neurotoxicity and, 426
U101017 and, 426
Hypoxia
ARL 15896AR and, 223
eliprodil and, 232
Hypoxia-ischemia, 3-NPA neurotoxic effects and, 146
Hypoxia/low glucose-induced neuronal cell damage, 267

Immune capacities, AlF_3 and NaF and, 162
Immunoglobulin, NaF and, 155
Immunoreactivity, PARP and, 369
In vitro model, hypoxia/low glucose-induced neuronal cell damage and, 267
In vivo potential neuroprotection, PARP and, 378
Infarct size, RSR-13 and, 251
Infarct volume, human stroke and, 281
Infarction
MCAO models and, 424
prolongation of ischemia and, 424
Inflammation, brain, recruited polymorphonuclear (PMN) and mononuclear leukocytes and, 179
Interleukin 1 receptor (IL-1RI), brain injury and, 181
Interleukin 1 receptor antagonist (IL-1ra), brain injury and, 181
Interleukin 1β (IL-1β), endothelium and, 179
Intracerebral hemorrhage (ICH), ARL 15896AR and, 229
Intraoperative neuroprotection, eras of, 288
^{125}Iodo-4-aminobenzyl-5′-*N*-methylcarboxamidoadenosine (I-AB-MECA), adenosine A_3 receptor and, 54

N^6-2-(3-Iodo-4-aminophenyl)ethyladenosine ([^{125}I]APNEA), adenosine A_3 receptor and, 50
Ionic channel action, ARL 15896AR and, 222
Ischemia
  brain, adenosine and, 13
  calpain activation and, 95
  ion channels and, 380
  NBQX and, 396
Ischemic brain, oxygen delivery enhancement and, 241
Ischemic penumbra, central area of necrosis surrounded by, 209

Kainic acid (KA)
  melatonin and, 71
  NMDA vs, 80, 93

L-type calcium channels, 383
Lactate, RSR-13 and, 251
Lactate dehydrogenase (LDH)
  adenosine A_3 receptor agonists and, 56
  heat shock protein and, 169
Lazaroid intraoperative neuroprotection and, 291
Leukocytes, recruited polymorphonuclear (PMN) and mononuclear, 179
Light, wavelengths of, melatonin and, 93
Long-term potential, hippocampal CA1 neurons and, 206
Long-term potentiation (LTP), eliprodil and, 233
Lubeluzole
  DCLHb and, 424
  window of, 423

Magnesium, head trauma and, 422
Malondialdehyde (MDA), melatonin and, 71
Malonic acid, ARL 15896AR and, 229
Mannitol, intraoperative neuroprotection and, 291
Measurement of drug exposure, 332
Melatonin
  excitotoxicity and, 85
  glutamate oxidative stress and, 79
  prophylactic actions of, 70
Melatonin administration, exogenous, endogenous melatonin production and, 91
Membrane fluidity, melatonin and, 91
Metalloproteases, focal stroke and, 186
Metallothioneins, regulation, function, and distribution of, 337
Metallothionen, acidosis or superoxide and, 403
Methylenedioxymethamphetamine (MDMA) neurotoxicity, 416
Methylmercury neurotoxicity, 334
1-Methyl-4-phenylpyridinium ion (MPP^+), heat shock proteins and, 169
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), heat shock proteins and, 167
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), hyperthermic response following, 207
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopamine neurotoxicity, 371
Methylprednisolone, spinal cord trauma and, 133
Microglial cells, adenosine and, 4
Microtubule-associated protein 2 (MAP-2)
  calcium-mediated changes in, 135
  chronic IB-MECA and, 59
Microvessels, cerebral, ischemic neuroprotection and, 97
Midazolam, aptiganel and, 420
Middle cerebral artery occlusion (MCAO)
  daytime and, 94
  lubeluzole and DCLHb and, 424
  temporary, 425
MK-801, eliprodil and, 233
Molecular cloning, adenosine A_3 receptor and, 49
Monocyte chemoattractant protein 1 (MCP-1), gene expression induced by ischemia and, 185
Morphological changes, dendritic, 135
mRNA level, calpain/β-actin and, 124
Multiple sclerosis (MS), neuregulin and, 404

N-Ethylcarboxaminoadenosine (NECA), adenosine A_3 receptor and, 50
N-Methyl-D-aspartate (NMDA)
  glutamate toxicity and, 211
  kainic acid and, 80, 93
N-Methyl-D-aspartate (NMDA) receptor antagonists
  clozapine and, 425
  low-affinity, ARL 15896AR and, 220
N-Methyl-D-aspartate (NMDA) receptor block, 240
N-Methyl-D-aspartate (NMDA) receptor subtypes, ARL 15896AR and, 239
N-Methyl-D-aspartate (NMDA) receptor-mediated neuroprotection, depolarization-induced neuroprotection and, 239

N-Methyl-D-aspartate (NMDA) receptor-operated channels, NMDA/Ca^{2+} and, 3
N-type calcium channels, 383
Nadroparin, 389
Necrosis
  apoptosis vs, 68
  TSEs and, 200
Neonatal hypoxic-ischemia, calpain proteolytic system and, 104
Nervous system insults, 428
Neuregulin
  EAE and, 403
  p75 and, 403
  spinal cord injury and, 404
Neuregulins, 348
Neurite outgrowth, cell survival and, 268
Neurodegeneration, excitotoxic-mediated, 216
Neurofilament, calpain activity and, 124
Neurological disorders, neuregulins and, 362
Neuronal death, calpain and, 122
Neuronal repair, calpain and, 133
Neurons, adenosine effects on, 2
Neurophysiological end points, moderate head injury studies and, 315
Neuroprotection
  cocaine dependence and, 323
  heparin and, 389
  ion channels and, 380
  NBQX and, 399
  NMDA-mediated, and neurotrophic factors, 211
  PARP and, 377
Neurotoxicity screening, 410
Neurotrophic activity, neuregulins and, 360
Neurotrophic factors, neuronal viability and, 215
Neutrophil, MCP-1 and, 185
Nicotinamide adenosine dinucleotide (NAD^+), PARP and, 366
Nimodipine
  hypertension and, 420
  intraoperative neuroprotection and, 291
  ischemic stroke and, 284
Nitric oxide synthase (NOS), chronic IB-MECA and, 60
3-Nitropropionic acid (3-NPA), hypoxia-ischemia and, 146
NOAEL, 412
Nocturnally active mammals, melatonin and, 92

Oligodendroglial development, neuregulins and, 351
Outcome observed vs predicted, 316
Oxidated neurotoxicity, melatonin and, 70
Oxygen delivery, infarct volume and, 279
Oxygen delivery enhancement, ischemic brain and, 241

P-type calcium channels, 383
p75, neuregulin and, 403
Parenteral form, pyrrolopyrimidines and, 426
Parkinson's disease
  adenosine A_{2A} receptors and, 36
  melatonin and, 73
Pathophysiology, adenosine-induced apoptosis and, 18
Penumbra, apoptotic cells as marker for, 276
Perinatal hypoxia-ischemia, compensatory long-term effect of, 146
Peripheral neuropathy, noninvasive methods of evaluating, 403
Pharmacological industry, academics and, 318
α-Phenyl-*N*-*tert*-butyl nitrone (PBN)
  ischemia and, 419
  neurite outgrowth and, 268
Phototherapy, melatonin and, 90
Poly(ADP-ribose) polymerase (PARP), 366
  cell death *in vivo* and, 404
  time course of changes in, 404
Poly(ADP-ribose) polymerase (PARP) inhibitors, 379
Preferential distribution, metallothioneins and, 338
Proliferating cell nuclear antigen (PCNA), GFAP vs, 198
Propentofylline, effects of CBF and, 68
Prophylactic actions of melatonin, 70
Proteases, calpain and, 104
Protection, adenosine and, 1
Psychosocial considerations, cocaine dependence and, 328
Pyrrolopyrimidines, 426

Q-type calcium channels, 383

R-Phenylisopropyladenosine (R-PIA), adenosine A_3 receptor and, 50
Reactive oxygen species (ROS), melatonin scavenging action and, 79
Receptor abuse-dependent antagonism (RADA), antiexcitotoxic therapy and, 85
Redbook II, 409
Regulatory mission, 407
Regulatory volume decrease, MeHg toxicity and, 339

Renal function tests, GV150526A and, 423
Reperfusion, blood flow and, 424
Riluzole
  HVA Ca^{2+} channel currents and, 405
  sodium channels and, 381
Risk assessment, quantitative, 414
Risk assessment process, 408
Rolipram, time window for neuroprotection and, 208
RSR-13, release of oxygen from hemoglobin and, 247

S-Phenylisopropyladenosine (S-PIA), adenosine A_3 receptor and, 50
Safety and tolerability, traumatic brain injury and, 314
Saturable carrier, AlF treatment and, 206
SCH 58261, adenosine A_{2A} receptors and, 34
Schwann cells, neuregulins and, 352
Second messenger systems, adenosine A_3 receptor and, 52
Secondary ischemic brain damage, 309
Sedatives, melatonin and, 91
Seizures
  adenosine A_{2A} receptors and, 35
  NBQX and, 395
Sequential analysis, 318
Sigma-I receptor action, ARL 15896AR and, 223
Sodium channel, riluzole, 381
Sodium fluoride (NaF), Alzheimer's dementia and, 153
Specific gravity, brain water content and, 259
Spectrin, brain, calpain-mediated proteolysis of, 105
Spinal cord injury
  calpain and, 120
  neuregulin and, 404
Spinal cord trauma, methylprednisolone and, 133
Striatal dopamine, PARP and, 372
Stroke
  human
    feline model of, 241
    infarct volume and, 281
    melatonin and, 93
    melatonin deficiency and, 87
    potential new therapeutic strategies for treatment of, 186
Stroke severity, clomethiazole and, 419
Succinate dehydrogenase (SDH), inhibitory effect of 3-NPA on, 146
Superoxide, metallothionen and, 403

Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (*see* TUNEL)
Tetrodotoxin-resistant sodium channels, 381
Tetrodotoxin-sensitive sodium channels, 381
Thrombolysis, ischemic stroke and, 283
Time course of changes, PARP and, 404
Time window
  adenosine A_1 receptor therapy and, 26
  different studies and, 422–423
  initiation of neuroprotective therapy and, 428
  lubeluzole and, 423
  NBQX and, 401
Toleration
  GV150526A and, 423
  human stroke and, 422
trans-(±)-1-Amino-1,3-cyclopentanedicarboxylic acid (t-ACPD), adenosine A_3 receptor and, 57
Transcription factors, gene expression induced by ischemia and, 185
Transduction mechanisms, adenosine A_3 receptor structure and, 51
Transferrin, iron and aluminum and, 206–207
Transient cat focal model, ARL 15896AR and, 226
Transient intraluminal focal model, ARL 15896AR and, 225
Transient spontaneously hypertensive rat (SHR) focal model, ARL 15896AR and, 225
Transmissible spongiform encephalopathies (TSEs), excitotoxic mechanisms of neurodegeneration in, 194
Trauma, NBQX and, 396
Traumatic brain injury, clinical trials in, 305
Tromethamine, intraoperative neuroprotection and, 291
Tumor necrosis factor-α (TNFα), endothelium and, 179
TUNEL assay
  melatonin deficiency and, 88
  silver stain and, 92

U101017, hypothermia and, 426
Uric acid, melatonin and, 90

Vasospasm, cerebral, proteolysis in, 98

Young rats, trauma in, 397
Younger animals, retraction and, 332

Index of Contributors

Page numbers in italics indicate participation in Questions and Answers

Abbracchio, M. P., 11–22, *68*, *208*
Abraham, D. J., 241–257
Acuña-Castroviejo, D., 70–78
Adami, M., 30–48
Ali, S. F., *68*, *91*, 167–178, *207*
Andrews, R. J., *93*, *132*, *207*, *279–280*, 288–304, *332*, *419–420*, *424*, *426*
Aschner, M., *206*, 334–347, *403*
Azam, M., 281–287

Banik, N. L., 120–127, 128–130, *133*
Bär, P. R., 267–278
Barone, F. C., 179–193
Bavbek, M., 95–103
Bertorelli, R., 30–48, *207*
Better, W., 323–327
Binienda, Z., 146–151
Bischofberger, N., 23–29
Blomgren, K., *90*, 104–119, *132–133*, *239*
Bona, E., 104–119
Brambilla, R., 11–22
Bullock, R., 241–257, *279–280*, 305–322, *332–333*, *422*, *424*

Cadet, J. L., 323–327, 328–331
Canoll, P. D., 348–365
Cappelletto, B., 95–103
Carney, J., *90*, *419*
Cattabeni, F., 11–22
Ceruti, S., 11–22
Choi, K. T., 258–266
Choi, S. C., 305–322
Colpaert, F., 366–379
Connor, J. A., 134–145
Cosi, C., 366–379, *404–405*
Cregan, E. F., 220–231

Degryse, A., 366–379
Deibler, G. E., 128–130
Depoortere, H., 232–238
Doppenberg, E. M. R., 241–257, 305–322
Dyker, A., *423*

Eisenberg, E., 281–287
Elmered, A., 104–119
Escames, G., 70–78

Facci, L., 366–379
Fergus, A., 95–103
Ferri, C., 30–48
Ferroni, S., 1–10
Feuerstein, G. Z., 179–193, *207–208*, *239*
Floreani, M., 79–84
Franceschi, C., 11–22
Françon, D., 232–238
Freyaldenhoven, T. E., 167–178

Gantt-Wilford, G., 120–127
Gendron, P., 220–231
Gerber, M. J., 241–257
Giusti, P., *69*, 79–84, 85–89, *93*, *133*, *420*
Grinspan, J. B., 348–365
Grotta, J., *133*, *419–420*, *423–425*
Grumet, S., 281–287
Guerrero, J. M., 70–78
Gusella, M., 79–84

Hagberg, H., 104–119
Hall, E., *279*, *403*, *424–427*
Herning, R. I., 323–327, 328–331, *420*
Hogan, E. L., 120–127
Hong, S.-C., 95–103
Huang, C.-S., 380–388

Ikonomidou, C., 394–402
Isaacson, R. L., *92*, 152–166, *206–207*

Jacobson, K. A., 11–22, 23–29
Jensen, K. F., 152–166
Jonas, S., *68*, *91–92*, 281–287 *332*, 389–393
Joosten, E. A. J., 267–278

Kanai, Y., 366–379
Kang, S.-D., 95–103
Kassell, N. F., 95–103
Kawashima, S., 104–119
King, D. E., 323–327, 328–331
Koek, W., 366–379
Kwan, A.-L., 95–103

Lee, D. M., 258–266
Lee, K. S., 95–103, *131*, *424*
Leem, J. K., 258–266
Lees, K. R., *420–423*
Lin, R. C. S., *94*, 134–145, *206*
Lipartiti, M., 79–84
Llinás, R., 389–393

Mahanthappa, N. K., 348–365
Malorni, W., 11–22
Manev, H., *68*, 79–84, 85–89, *92–94*, *131–132*, *239*, *426*
Marchini, C., 1–10
Marchionni, M. A., *131*, 348–365, *403–404*
Marien, M. R., 366–379
Marini, A. M., 209–219, *239*, *403*, *425*
Matesic, D. F., 134–145
Matzelle, D., 120–127
McRae, A., 104–119
Menegazzi, M., 366–379
Milani, D., 366–379
Miller, J. A., 220–231
Mocchetti, I., 209–219
Mueller, A., *239*, *405*, *422*

Narahashi, T., *90*, *240*, 380–388, *405*, *421*

Ogata, T., 1–10
Ongini, E., 30–48
Ono, T., 104–119

Palmer, G. C., 220–231, *239–240*, *419–421*, *425*
Pappolla, M. A., 70–78
Peeling, J., 220–231

Reiter, R. J., 70–78, *90–93*, *207*
Rudolphi, K., 1–10

Saido, T. C., 104–119
Salzer, J. L., 348–365
Santamaria, R., 232–238
Scallet, A. C., 194–205
Scatton, B., 232–238
Scherer, S. S., 348–365
Schoepp, D. D., *421*
Schubert, P., 1–10, *68*, *206*, *279*
Shields, D. C., 128–130
Simmons, R., *425*
Skaper, S. D., 366–379
Slikker, W., Jr., ix, *68*, *91–93*, *332*, *403–404*, 406–418, *419*, *422–423*, *426*, 428–430
Sobotka, T. J., 406–418
Sodaar, P., 267–278
Song, J.-H., 380–388
Spiga, G., 209–219
Strous, G., 267–278
Sugimori, M., 389–393
Suh, B. T., 258–266
Suzuki, H., 366–379

Tabor, M. P., 267–278
Tizzano, J., *422*
Toyoda, T., 95–103
Tran, A. Q., 281–287
Trembly, B., ix, *91*, *279*, *404*, 428–430
Turski, L., *208*, 394–402, *422*

Uz, T., 85–89

Van der Worp, H. B., 267–278
Vantini, G., 366–379
Varner, J. A., 152–166
Veldman, H., 267–278
Viera, D., 281–287
von Lubitz, D. K. J. E., 11–22, 23–29, 49–67, *69*

Wang, X., 179–193
Watson, J. C., 241–257
Weber, E., *421*
Williams, C., *403–404*, *426*

Yanamoto, H., 95–103
Ye, X., 194–205
Yeh, J. Z., 380–388

Zauner, A., 241–257